Chong Kun Dang Pharmaceutical Corp.
13
2
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.7%
1 terminated/withdrawn out of 13 trials
66.7%
-19.8% vs industry average
38%
5 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Role: collaborator
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Role: collaborator
Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance
Role: collaborator
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
Role: collaborator
Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
Role: collaborator
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients
Role: collaborator
Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment
Role: collaborator
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract
Role: collaborator
Assessment of Change in Atherosclerotic Plaque by Serial CCTA
Role: collaborator
Immediate Release Versus Slow Release Carvedilol in Heart Failure
Role: collaborator
Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation
Role: collaborator
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
Role: collaborator
Pharmacokinetic Comparisons of Two Donepezil Formulations
Role: collaborator
All 13 trials loaded